Table 1.
Pathway enrichment for 11 male and female rat tissue signature lists
| 11 male and female tissues | Sex and tissue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | |||||||||||||
| 6 tissues | Heart | Kidney | Liver | Prostate | SV | Testis | 5 tissues | Heart | Kidney | Liver | Ovary | Uterus | ||
| Pathway name | ||||||||||||||
| Number of genes in input list | 4059 | 3046 | 172 | 725 | 266 | 1112 | 274 | 552 | 1298 | 408 | 151 | 99 | 305 | 279 |
| Total number of affected pathways | 230 | 224 | 79 | 151 | 141 | 191 | 90 | 99 | 191 | 108 | 79 | 29 | 80 | 138 |
| Pathways in cancer | 45 | 32 | 3 | 7 | 6 | 13 | 1 | 2 | 17 | 6 | 3 | 1 | 3 | 4 |
| Protein processing in endoplasmic reticulum | 39 | 38 | 3 | 4 | 1 | 22 | 5 | 4 | 3 | 1 | 1 | 1 | ||
| HTLV-I infection | 39 | 31 | 8 | 3 | 14 | 3 | 2 | 10 | 4 | 2 | 1 | 3 | ||
| RNA transport | 39 | 31 | 1 | 8 | 17 | 3 | 6 | 11 | 4 | 1 | 2 | 4 | ||
| Transcriptional misregulation in cancers | 31 | 26 | 1 | 8 | 6 | 7 | 4 | 3 | 12 | 6 | 3 | 1 | 3 | |
| Herpes simplex infection | 30 | 23 | 2 | 10 | 3 | 7 | 2 | 1 | 9 | 3 | 1 | 2 | 3 | |
| Lysosome | 29 | 27 | 1 | 5 | 4 | 16 | 2 | 2 | 5 | 1 | 1 | 3 | ||
| Ribosome | 29 | 27 | 2 | 5 | 1 | 20 | 4 | 1 | 1 | 2 | ||||
| Endocytosis | 29 | 26 | 1 | 4 | 8 | 11 | 1 | 3 | 5 | 2 | 3 | |||
| Phagosome | 28 | 27 | 1 | 6 | 6 | 12 | 2 | 7 | 3 | 4 | ||||
| MAPK signaling pathway | 28 | 21 | 1 | 7 | 3 | 7 | 1 | 2 | 8 | 3 | 1 | 4 | ||
| Spliceosome | 27 | 17 | 8 | 1 | 1 | 2 | 7 | 12 | 6 | 1 | 1 | 5 | ||
| Regulation of actin cytoskeleton | 26 | 24 | 1 | 6 | 6 | 9 | 3 | 5 | 3 | 1 | 1 | |||
| Alzheimer's disease | 26 | 22 | 2 | 4 | 7 | 10 | 5 | 2 | 3 | |||||
| Huntington's disease | 26 | 22 | 1 | 6 | 2 | 14 | 5 | 1 | 1 | 2 | 1 | |||
| Purine metabolism | 26 | 22 | 1 | 6 | 2 | 4 | 2 | 6 | 7 | 2 | 5 | |||
| Focal adhesion | 26 | 21 | 2 | 2 | 7 | 8 | 3 | 9 | 3 | 2 | 4 | |||
| Chemokine signaling pathway | 24 | 23 | 3 | 4 | 6 | 9 | 1 | 1 | 4 | 2 | 2 | |||
| Pyrimidine metabolism | 24 | 20 | 1 | 6 | 1 | 6 | 1 | 5 | 6 | 1 | 1 | 1 | 3 | |
| Tuberculosis | 24 | 20 | 6 | 6 | 9 | 1 | 9 | 1 | 1 | 7 | ||||
| Influenza A | 23 | 21 | 1 | 5 | 2 | 11 | 1 | 3 | 5 | 1 | 2 | 2 | ||
| Oxidative phosphorylation | 23 | 20 | 1 | 4 | 5 | 11 | 5 | 1 | 1 | 3 | ||||
| Leukocyte transendothelial migration | 22 | 18 | 2 | 1 | 7 | 8 | 1 | 6 | 4 | 1 | 1 | |||
| Cytokine-cytokine receptor interaction | 21 | 19 | 1 | 6 | 7 | 6 | 4 | 3 | 1 | |||||
| Osteoclast differentiation | 21 | 18 | 1 | 2 | 6 | 10 | 1 | 5 | 1 | 1 | 3 | |||
| Cell adhesion molecules | 20 | 14 | 2 | 3 | 4 | 6 | 1 | 7 | 3 | 1 | 1 | 2 | ||
| Insulin signaling pathway | 19 | 13 | 2 | 3 | 6 | 2 | 6 | 2 | 4 | |||||
| mRNA surveillance pathway | 19 | 13 | 1 | 4 | 5 | 2 | 4 | 8 | 4 | 2 | 2 | |||
HTLV, human T-lymphotropic virus; MAPK, mitogen-activated protein kinase; SV, seminal vesicle.